MICROPARTICLE DNA VACCINE AGAINST SIV

针对 SIV 的微粒 DNA 疫苗

• 批准号: 7716165
• 负责人: Luis David Giavedoni
• 金额: $ 0.15万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716165
• 关键词: Animal Model; Biodegradable microsphere; Computer Retrieval of Information on Scientific Projects Database; DNA; DNA Vaccines; Development; Disease; Funding; Goals; Grant; HIV Infections; HIV-1; Human; Infection; Infection prevention; Institution; Macaca; Macaca mulatta; Mucosal Immune Responses; Mucous Membrane; Research; Research Personnel; Resources; SIV; Sexually Transmitted Diseases; Source; Surface; Technology; Testing; United States National Institutes of Health; Vaccines; Vagina; Viral Proteins; novel; research study; transmission process; vaccine delivery

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Currently, more than 40 million people worldwide are persistently infected with HIV-1, and the main mode of transmissions for new infections is by sexual contact. Development and implementation of an effective vaccine that would prevent infection is a logical approach to controlling the spread of the disease. Infection of rhesus macaques with the simian immunodeficiency virus (SIV) is the best animal model for HIV infection in humans. The goal of this project is to test a novel form of vaccine delivery, i.e., the application to a mucosal surface of biodegradable microspheres loaded with DNA encoding SIV proteins. We will compare the efficacy in inducing anti-SIV systemic and mucosal immune responses in macaques given a DNA vaccine via the vaginal or intranasal mucosa. These experiments will produce useful information about a vaccine technology that can also be applied to many other sexually transmitted diseases.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目前，全世界有4 000多万人持续感染艾滋病毒-1，新感染的主要传播方式是性接触。开发和实施一种有效的预防感染的疫苗是控制疾病传播的合理方法。用猴免疫缺陷病毒（SIV）感染恒河猴是人类HIV感染的最佳动物模型。该项目的目标是测试一种新的疫苗输送形式，即，将载有编码SIV蛋白的DNA的可生物降解的微球应用于粘膜表面。我们将比较通过阴道或鼻内粘膜给予DNA疫苗的猕猴诱导抗SIV全身和粘膜免疫应答的功效。这些实验将产生关于疫苗技术的有用信息，这种疫苗技术也可以应用于许多其他性传播疾病。